tirzepatide + niacinamide vs tirzepatide Patients GLOWING on Compounded with Understanding the Difference: While both

We sat down with our founder, CEO, and Father of Detox to better understand why and how he incorporates this practice into his personal biohacking regimen

Development of a quintuple agonist that outperforms GLP-1R agonism in obese mice has recently been reported by Liskiewicz and colleagues They set out to design a unimolecular quintuple agonist that combines GLP-1RGIPR co-agonism with the insulin-sensitizing and anti-inflammatory effects of lanifibranor, a triple agonist of three peroxisome proliferator-activatedreceptors, PPAR// Its efficacy in reducing body weight improving glucose control and suppressing inflammation markedly outperforms all currently available agents The original paper can be found here: To view or add a comment, sign in Proud to announce our new publication in Hepatology International (Impact Factor 7.9 | Q1)

TIPO Clinical trial program evaluating tesofensine for obesity treatment 203 Participants in the pivotal Phase 2b trial (TIPO-1) Questions No, tesofensine is not yet FDA approved

Glutamine-derived -KG enters the TCA cycle and in many cell lines contributes more carbon to TCA cycle intermediates than glucose

This finding provides insight into how the ER sets redox balance and provides a framework to define how ER metabolism is controlled and coupled to ER function in physiology and disease